Trikaya Global Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Trikaya Global Pharmaceutical Export Portfolio Dataset — 6 Products, $92.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Trikaya Global — Pharmaceutical Exporter Profile (2026) | 6 Products, $92.8K Trade | TransData Nexus

Trikaya Global

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $92.8K Total Trade · DGFT Verified

Trikaya Global is an Indian pharmaceutical exporter with a total trade value of $92.8K across 6 products in 3 therapeutic categories. Based on 58 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ifosfamide ($50.7K), Cladribine ($12.0K), Teicoplanin ($11.2K).

Trikaya Global — Export Portfolio & Destination Treemap

Trikaya Global pharmaceutical export portfolio — 6 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Trikaya Global? — Company Overview & Market Position

Trikaya Global is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2006, the company is headquartered in Mumbai, Maharashtra, India. The registered office is located at Unit No. 1, Sea-view Annexe, No. 18, S. V. Road, Vile Parle West, Mumbai, Maharashtra - 400 002, India. The company operates as a private limited entity, with a paid-up capital of ₹0.10 million, as per the latest available records. Specific details regarding the ownership structure, Corporate Identification Number (CIN), revenue, and employee count are not publicly disclosed. The company's official website is not available, and contact information such as telephone and email addresses are not provided in the available sources.

What Does Trikaya Global Export? — Product Portfolio Analysis

Top Products by Export Value

1Ifosfamide$50.7K 2Cladribine$12.0K

Product Portfolio — Top 6 by Export Value

Trikaya Global exports 6 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ifosfamide	Advanced Oncology	$50.7K	15	2.1%	9
2	Cladribine	Advanced Oncology	$12.0K	7	5.1%	3
3	Teicoplanin	Advanced Antibiotics	$11.2K	11	0.2%	11
4	Brufen	Brand Names & OTC Products	$8.4K	7	0.2%	12
5	Daunorubicin	Advanced Oncology	$8.2K	11	1.2%	10
6	Cabozantinib	Advanced Oncology	$2.4K	7	1.9%	12

Trikaya Global exports 6 pharmaceutical products across 3 therapeutic categories with a total export value of $92.8K. The top category is Advanced Oncology (78.9% of portfolio), followed by Advanced Antibiotics (12.0%), indicating a concentrated portfolio with the top 5 products accounting for 97.5% of total export value.

Trikaya Global — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Trikaya Global's manufacturing facilities are not explicitly detailed in the available sources. The company is primarily engaged in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. However, specific information regarding the locations, capacities, and specializations of its manufacturing plants is not publicly available.

3Key Leadership

The available sources do not provide specific information about the key leadership of Trikaya Global, including the CEO, CFO, or other key executives. The company's registered office is located at Unit No. 1, Sea-view Annexe, No. 18, S. V. Road, Vile Parle West, Mumbai, Maharashtra - 400 002, India. However, detailed information about the leadership team is not publicly disclosed.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Trikaya Global Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Trikaya Global's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available sources. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top five exported products include Ifosfamide, Cladribine, Teicoplanin, Brufen, and Daunorubicin, with Ifosfamide leading at $51,000 USD and a 2.1% market share. However, specific information regarding regulatory filings, approvals, and market access status in these regions is not publicly available.

2Emerging Markets

Trikaya Global's penetration into emerging markets such as Africa, Latin America, and Southeast Asia is not explicitly detailed in the available sources. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, specific information regarding the company's presence in emerging markets and WHO prequalification enabling access is not publicly available.

3Geographic Strategy

Trikaya Global — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Trikaya Global's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top five exported products include Ifosfamide, Cladribine, Teicoplanin, Brufen, and Daunorubicin. However, detailed information regarding FDA approvals and inspection history is not disclosed in the available sources.

2WHO & EU GMP

Specific information regarding Trikaya Global's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding WHO and EU GMP certifications is not disclosed in the available sources.

CDSCO & Indian Regulatory

Trikaya Global — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Specific information regarding Trikaya Global's top competitors in overlapping categories, market share comparison, and head-to-head analysis is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding the competitive landscape is not disclosed in the available sources.

2Key Differentiators

Specific information regarding Trikaya Global's unique strengths, competitive advantages, and product portfolio distinctions is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding the company's key differentiators is not disclosed in the available sources.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Trikaya Global as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Specific information regarding Trikaya Global's overall track record, export volume and consistency, and reliability indicators is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding the company's supplier assessment is not disclosed in the available sources.

2Certifications to Verify

Specific certifications that importers should verify for Trikaya Global, such as FDA approvals, WHO-GMP, EU GMP, and ISO certifications, are not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding the company's certifications is not disclosed in the available sources.

3Due Diligence Checklist

Frequently Asked Questions — Trikaya Global

How many pharmaceutical products does Trikaya Global export from India?

Trikaya Global exports 6 pharmaceutical products across 3 therapeutic categories. The top exports are Ifosfamide ($50.7K), Cladribine ($12.0K), Teicoplanin ($11.2K), Brufen ($8.4K), Daunorubicin ($8.2K). Total export value is $92.8K.

What is Trikaya Global's total pharmaceutical export value?

Trikaya Global's total pharmaceutical export value is $92.8K, based on 58 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Trikaya Global cover?

Trikaya Global exports across 3 therapeutic categories. The largest are Advanced Oncology (78.9%, 4 products), Advanced Antibiotics (12.0%, 1 products), Brand Names & OTC Products (9.0%, 1 products).

Get Full Trikaya Global Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.